NIH BRG R01 Guide 2026: Eligibility
Updated 8 official sources
Quick Answer: NIH BRG R01 eligibility is strongest when an applicant team can show a real bioengineering contribution, a biomedical problem, and an R01-scale plan under the PAR-27-072 cap of less than $500,000 in direct costs per year.
Full answer and how we checked it
BRG is not a generic technology label. If the project mainly tests a biological hypothesis with an existing tool, a parent R01 or R21 may be better.
Who this is for: Biomedical engineering faculty, cancer technology teams, university research offices, and clinical collaborators deciding whether BRG is the right route before writing an NIH R01.
Data note: This guide uses NIH PAR-27-072, NIH R01 activity guidance, NIH clinical-trial policy, the live Bioengineering Research Grants BRG R01 program page, NOT-NS-26-042, and USAspending.gov award data, checked on October 10, 2026.
In this guide
The BRG R01 exists for a narrower reason than many teams assume. According to NIH PAR-27-072, the program encourages collaborations between life science and physical science teams that apply a multidisciplinary bioengineering approach to a biomedical problem. That means the page is not asking only whether the investigator is eligible. It is asking whether the project is truly a BRG project.
Use this guide with the live BRG R01 program page, then compare the route with NIH R01, R21, R03, and K awards, NIH grants complete guide, and how grant reviewers score applications. Strong engineering teams can lose time by treating BRG as a broad home for any device, software, or assay. The strongest BRG concepts make the engineering method and biomedical decision inseparable.
Where official sources stop: NIH PAR-27-072 defines the BRG route, but it does not grade whether the engineering work is central enough to deserve this R01 branch. Our screen requires the method, model, tool, assay, device, or system to change the biomedical decision itself. If the technology only supports a standard biological question, the team should compare parent R01, R21, R03, SBIR/STTR, or institute-specific routes before drafting.
October 2026 Source Check: PAR-27-072 BRG R01
PAR-27-072 is current as of October 10, 2026. NIH posted it on May 4, 2026, and it uses NIH standard due dates: the first were October 5, 2026 for new applications and November 5, 2026 for renewals, resubmissions, and revisions, followed by February 5 and March 5, 2027. The notice expires July 6, 2029. NOT-NS-26-042 (opens in a new tab) (August 28, 2026) added NINDS as a participating institute for due dates on or after October 5, 2026, so the participating ICs are now NCI, NEI, NICHD, and NINDS. The useful applicant question is not whether the notice exists. The useful question is whether the project needs a bioengineering R01 rather than a parent R01, R21, R03, or SBIR/STTR route.
| Source checked October 10, 2026 | Applicant decision |
|---|---|
| PAR-27-072 revised full announcement on Grants.gov (opens in a new tab) | Confirms BRG purpose, participating ICs, eligibility, clinical-trial-optional status, budget cap, and 5-year maximum period |
| Simpler Grants opportunity listing (opens in a new tab) | Confirms the active public listing and posted attachment path |
| NOT-NS-26-042 (opens in a new tab) | Adds NINDS for due dates on or after October 5, 2026 |
| NIH R01 activity code page (opens in a new tab) | Confirms R01 is the base research project grant, but not a substitute for NOFO-specific fit |
| NIH clinical trial decision tool (opens in a new tab) | Use before choosing a trial form set, even when the notice says clinical trial optional |
| NIH simplified review framework (opens in a new tab) | Confirms most research project applications now face the 2025 review framework |
Do not use broad assistance-listing award totals as a BRG award forecast. PAR-27-072 lists 8 assistance listings that cover whole institutes' research portfolios, and PAR-27-072 itself limits application budgets to less than $500,000 in direct costs per year and does not promise a set number of awards.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
NIH BRG R01 Eligibility: 4 Fit Tests
4 fit tests should be passed before the team writes, because the wrong R01 branch can cost a full NIH cycle. According to PAR-27-072, BRG accepts new, renewal, resubmission, and revision applications and covers many applicant organization types, including higher education, nonprofits, for-profits, governments, and faith-based or community-based organizations.
| Fit test | Strong BRG signal | Red flag |
|---|---|---|
| Engineering role | The method, model, tool, or design changes what can be measured or done | Existing technology is only being used as a service |
| Biomedical problem | The problem is specific to disease, biology, translation, or care | The work is mainly platform development without a clear use case |
| Team shape | Engineering and biomedical investigators both own parts of the plan | One side is named but not needed |
| R01 scale | The work needs up to 5 years and a full research-project frame | A 2-year pilot or small validation study would answer the question |
The common mistake is assuming that "bioengineering" in the lab name is enough. It isn't. Reviewers need to see the bioengineering work doing scientific work, not decorating a standard proposal.
Clinical-Trial Optional Does Not Mean Any Trial
5 years of project work can still be a poor fit if the clinical-trial logic is wrong. PAR-27-072 says the opportunity is clinical trial optional, but it also says BRG is not meant to support conventional clinical trials that lack translation as the main motivation, and it will not support phase III clinical trials.
| Project type | BRG posture |
|---|---|
| Tests device function or validates performance in a chosen setting | Stronger fit |
| Uses human specimens to validate a measurement tool | Possible fit if the engineering question is central |
| Runs a late-stage treatment trial | Weak fit |
| Applies an existing assay to a disease cohort without method work | Weak fit |
According to NIH, the application budget is limited to less than $500,000 in direct costs per year, and the maximum award period is 5 years. PAR-27-072 lists 8 assistance listings, including 93.399, NCI's Cancer Control listing. According to USAspending.gov (opens in a new tab) data, 93.399 had about $167.0M in FY2024 obligations across 150 awards, but that total covers all NCI cancer-control grants, not BRG awards, so it says nothing about BRG odds.
BRG vs Parent R01, R21, R03, and SBIR
6 route choices often sit near BRG, and picking the wrong one changes the review story. If the engineering contribution is early and risky, R21 may be cleaner. If the work is a small dataset, secondary analysis, or narrow feasibility test, R03 may fit better. If the applicant is a company building a product with commercialization as the main path, SBIR or STTR may be the better first read.
| Route | Better first read when... | Why it may beat BRG |
|---|---|---|
| BRG R01 | Engineering and biomedical questions are joined | Program intent matches the work |
| Parent R01 | The hypothesis is biological and the tool already exists | Review can focus on science, not engineering fit |
| R21 | The concept is too early for R01-scale evidence | Smaller scope may be more honest |
| R03 | The project is a small, self-contained test | Less budget and shorter period fit the work |
| SBIR/STTR | A small business owns the product path | Commercial readiness is part of the score |
| Institute-specific NOFO | One IC has a narrow technology priority | Program fit is clearer |
For broader NIH route choice, use NIH R01 vs R21 vs R03 vs K awards. For the live award record and source links, use the BRG R01 program page.
What NIH Doesn't Tell You
Large institute award totals can look encouraging, but NIH's public page cannot tell you whether the proposal reads like a BRG concept. It gives rules. It does not make the route decision for the team.
First, NIH does not grade the center of gravity of the application before submission. A draft can have an exciting engineering aim while Aim 2 and Aim 3 drift into ordinary biology. That is a red flag because the study section may ask why the project belongs in BRG at all.
Second, NIH does not compare BRG against company-oriented routes. A for-profit applicant may be eligible, but eligibility is not the same as fit. If the core goal is product development, reimbursement, manufacturing, or market entry, the team should test SBIR/STTR before defaulting to BRG.
Third, NIH does not tell you when a clinical validation plan has become a conventional clinical trial. The BRG trial language rewards function testing and performance validation. It does not reward a late-stage intervention study with a thin engineering frame.
Fourth, NIH does not publish BRG-only award totals in the notice, and the assistance listings attached to PAR-27-072 mix BRG awards with every other grant those institutes make. NIH RePORTER searches by notice number are a better check on what BRG has funded. Then force a yes or no answer on mechanism fit.
The downside of choosing BRG too loosely is simple: the proposal can be technically eligible and still scored poorly because reviewers do not see why this NOFO was chosen. That is the trap.
5 Real-World BRG Scenarios
5 scenarios show where the route decision changes. A university in Massachusetts building a new imaging method for early tumor detection may have a strong BRG case if the method changes what clinicians can see and the validation plan is clear. A lab in Ohio using a purchased imaging platform to test a cancer hypothesis may belong on a parent R01 instead.
| Scenario | Better route | Why |
|---|---|---|
| New sensor validated for a specific disease decision | BRG R01 | Engineering and biomedical value are joined |
| Existing sequencing method applied to a cohort | Parent R01 | Tool work is not central |
| Early proof-of-concept model with limited data | R21 | Scope may be too early for R01 |
| Startup testing a commercial device prototype | SBIR/STTR | Company route may fit better |
| Small validation using stored samples | R03 or targeted R21 | Smaller project may be enough |
One investigator at a university in California might build a predictive model that changes how transplant rejection is detected before symptoms. That can be BRG if the model, data, and biological question are inseparable. One company in Texas might already have a prototype and mainly need customer discovery plus regulatory planning. That second case may be stronger as SBIR/STTR.
BRG Readiness Checklist to Run First
7 draft checks can prevent a weak BRG submission. The strongest BRG drafts answer the fit question in the first page.
- The specific aims name the bioengineering contribution.
- The biomedical problem is not generic.
- Each aim needs both technical and biological review.
- The clinical-trial status is matched to PAR-27-072.
- The budget stays below the direct-cost cap.
- The team includes the skills to build and test the method.
- The route choice is better than parent R01, R21, R03, or SBIR/STTR.
According to NIH PAR-27-072, applications must follow NIH application rules and the NOFO-specific instructions. PAR-27-072 doesn't promise a set number of awards, so the strongest move is still a sober fit check before writing.
According to NIH's clinical trial decision tool, a study can meet the NIH clinical trial definition if 4 answers are yes: human participants, prospective assignment, an intervention effect, and a health-related biomedical or behavioral outcome. That matters for BRG because "clinical trial optional" is not a casual label. One device-validation aim can change the form set, review expectations, and registration duties. Before drafting, use the NIH decision tool alongside PAR-27-072 and write the clinical-trial status into the first-page route memo.
Sources
- NIH PAR-27-072 BRG revised full announcement: Grants.gov listing 360543 (opens in a new tab)
- NIH NOT-NS-26-042, NINDS participation: grants.nih.gov (opens in a new tab)
- Simpler Grants PAR-27-072 opportunity listing: simpler.grants.gov (opens in a new tab)
- NIH R01 activity code page: grants.nih.gov (opens in a new tab)
- NIH application guide: grants.nih.gov (opens in a new tab)
- NIH clinical trial decision tool: grants.nih.gov (opens in a new tab)
- NIH simplified review framework: grants.nih.gov (opens in a new tab)
- Grantsights BRG R01 program page: Bioengineering Research Grants BRG R01
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open BRG program page
Check PAR-27-072, budget cap, trial status, IC fit, and source links before drafting.
Compare parent R01
Use when the engineering work supports a standard biomedical hypothesis rather than driving the route.
Compare NIH mechanisms
Choose between BRG, parent R01, R21, R03, K, SBIR, and institute-specific routes.
Check review risk
Turn method, team, budget, trial status, and review-home questions into score risks.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
Who is the NIH BRG R01 for?
The BRG R01 is for teams using bioengineering, physical science, quantitative science, or engineering methods to solve a specific biomedical, translational, or clinical problem.
Does BRG allow clinical trials?
PAR-27-072 is clinical trial optional, but it supports trials that test function or validate performance. It is not meant for conventional phase III clinical trials.
What is the BRG budget cap?
PAR-27-072 limits application budgets to less than $500,000 in direct costs per year, with a maximum project period of 5 years.
Who should skip BRG?
Skip BRG if the project is a standard biomedical hypothesis with no tool, method, model, design, device, assay, system, or engineering contribution.
What should applicants compare against BRG?
Compare BRG against a parent R01, R21, R03, SBIR/STTR, institute-specific technology NOFO, and foundation technology-development routes before writing.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
NIH Grants 2026: R01, K Awards, R21, R35, SBIR
Compare NIH R01, K awards, R21, R03, R35, SBIR/STTR, success rates, deadlines, and program pages before choosing a route.
Latin America health disparities R01 eligibility Guide
NIMHD ended PAR-25-342 early on June 3, 2026. What the Latin America R01 covered, 8 fit checks, and where to look for current NIMHD funding.
NIH Institutional K12 Guide 2026: Eligibility
NIH institutional K12 guide for 2026: eligibility, scholar fit, 75% effort, CTSA K12 rules, mentors, K08/K23/KL2 comparisons.
How to Read an NIH Summary Statement: Scores and Critiques
Your NIH summary statement has 3 reviewers' critiques and, if discussed, a 10-90 impact score. Decode the wording and decide: resubmit, revise or switch.
NIH Resubmission (A1): 1 Try, 37 Months, 1-Page Intro
NIH allows one A1 resubmission within 37 months of the A0, with a one-page Introduction. When to resubmit, when to go new, and how to answer reviewers.
NIH Specific Aims Page: 1-Page Structure and 2-3 Aims
Write the 1-page NIH Specific Aims: what is known, the gap, your objective and hypothesis, then 2-3 independent aims with expected outcomes and impact.